Vermutlich ist es ein "Klassen-Effekt" der mRNA-LNP Plattform. Diese führt zu einer Aktivierung des angeborenen Immunsystems, was sekundär CD8 T Zellantworten verstärkt. Der beobachtete Effekt war in Kombination mit einer Checkpunkt-Blockade (PDL1-Antikörper) bei NSCLC und Melanom.
October 22, 2025 at 8:56 PM
Vermutlich ist es ein "Klassen-Effekt" der mRNA-LNP Plattform. Diese führt zu einer Aktivierung des angeborenen Immunsystems, was sekundär CD8 T Zellantworten verstärkt. Der beobachtete Effekt war in Kombination mit einer Checkpunkt-Blockade (PDL1-Antikörper) bei NSCLC und Melanom.
"Acquired resistance to PDL1 inhibition can rewire the ifn-regulated secretory machinery in tumor cells, altering the immune microenvironment. These secretory programs may be exploited as biomarkers & therapeutic targets following treatment failure"
#Immunology
www.embopress.org/doi/full/10....
#Immunology
www.embopress.org/doi/full/10....
December 19, 2024 at 6:26 PM
"Acquired resistance to PDL1 inhibition can rewire the ifn-regulated secretory machinery in tumor cells, altering the immune microenvironment. These secretory programs may be exploited as biomarkers & therapeutic targets following treatment failure"
#Immunology
www.embopress.org/doi/full/10....
#Immunology
www.embopress.org/doi/full/10....
There are therapies using antibodies. The oldest use is as antiserum; antibodies used when you are bitten by a snake or spider, to neutralise the venom or after a dog bite to inhibit the rabies virus.
Others are used in, for example, cancer therapy; anti-PDL1 and -CTLA4.
5/10
Others are used in, for example, cancer therapy; anti-PDL1 and -CTLA4.
5/10
October 26, 2024 at 10:59 AM
There are therapies using antibodies. The oldest use is as antiserum; antibodies used when you are bitten by a snake or spider, to neutralise the venom or after a dog bite to inhibit the rabies virus.
Others are used in, for example, cancer therapy; anti-PDL1 and -CTLA4.
5/10
Others are used in, for example, cancer therapy; anti-PDL1 and -CTLA4.
5/10
pour leur publication sur les rejets de greffe sous immunothérapie anticancéreuse.
📰 Les inhibiteurs de PDL1 pourraient être associés à un risque moindre de rejet de greffe par rapport aux inhibiteurs de PD1 et CTLA4 : analyse de la base de pharmacovigilance de l'OMS
📰 Les inhibiteurs de PDL1 pourraient être associés à un risque moindre de rejet de greffe par rapport aux inhibiteurs de PD1 et CTLA4 : analyse de la base de pharmacovigilance de l'OMS
January 29, 2025 at 5:29 PM
pour leur publication sur les rejets de greffe sous immunothérapie anticancéreuse.
📰 Les inhibiteurs de PDL1 pourraient être associés à un risque moindre de rejet de greffe par rapport aux inhibiteurs de PD1 et CTLA4 : analyse de la base de pharmacovigilance de l'OMS
📰 Les inhibiteurs de PDL1 pourraient être associés à un risque moindre de rejet de greffe par rapport aux inhibiteurs de PD1 et CTLA4 : analyse de la base de pharmacovigilance de l'OMS
My mom is the adverse effect queen - the common ones *and* some out-there examples. Her off-target effect from PDL1 therapy was… incredibly painful tendinitis. (And here I am going “thank god it’s the shoulder and not the liver”)
February 11, 2024 at 1:11 PM
My mom is the adverse effect queen - the common ones *and* some out-there examples. Her off-target effect from PDL1 therapy was… incredibly painful tendinitis. (And here I am going “thank god it’s the shoulder and not the liver”)
Temel highlighting that #PalliativeCare is more than physical symptom management.
She notes that she and her fellow oncologists should not rely on clinical characteristics of cancer alone to know when palliative care should be involved.
(The second slide is what NOT to do)
She notes that she and her fellow oncologists should not rely on clinical characteristics of cancer alone to know when palliative care should be involved.
(The second slide is what NOT to do)
February 7, 2025 at 4:20 PM
Temel highlighting that #PalliativeCare is more than physical symptom management.
She notes that she and her fellow oncologists should not rely on clinical characteristics of cancer alone to know when palliative care should be involved.
(The second slide is what NOT to do)
She notes that she and her fellow oncologists should not rely on clinical characteristics of cancer alone to know when palliative care should be involved.
(The second slide is what NOT to do)
Amazing to see recent NICE approvals:
1. Neoadjuvant alone (CM816): all PDL1
2. Perioperative (KN671, AGEAN) : all PDL1
3. Adjuvant (IMP010, TPS 50+; KN091 all PDL1)
4. Adjuvant EGFRm (ADAURA)
5. Adjuvant ALK+ (ALINA)
Biomarker testing in early #NSCLC now critical!
1. Neoadjuvant alone (CM816): all PDL1
2. Perioperative (KN671, AGEAN) : all PDL1
3. Adjuvant (IMP010, TPS 50+; KN091 all PDL1)
4. Adjuvant EGFRm (ADAURA)
5. Adjuvant ALK+ (ALINA)
Biomarker testing in early #NSCLC now critical!
December 21, 2024 at 10:43 AM
Amazing to see recent NICE approvals:
1. Neoadjuvant alone (CM816): all PDL1
2. Perioperative (KN671, AGEAN) : all PDL1
3. Adjuvant (IMP010, TPS 50+; KN091 all PDL1)
4. Adjuvant EGFRm (ADAURA)
5. Adjuvant ALK+ (ALINA)
Biomarker testing in early #NSCLC now critical!
1. Neoadjuvant alone (CM816): all PDL1
2. Perioperative (KN671, AGEAN) : all PDL1
3. Adjuvant (IMP010, TPS 50+; KN091 all PDL1)
4. Adjuvant EGFRm (ADAURA)
5. Adjuvant ALK+ (ALINA)
Biomarker testing in early #NSCLC now critical!
PD1 & PDL1 Inhibitor Market – Dynamics: Regional Breakdown and Analysis
This report presents a comprehensive analysis of the PD1 & PDL1 Inhibitor Market, providing stakeholders with valuable insights into its growth trajectory, opportunities, and challenges. The study explores key market dynamics,…
This report presents a comprehensive analysis of the PD1 & PDL1 Inhibitor Market, providing stakeholders with valuable insights into its growth trajectory, opportunities, and challenges. The study explores key market dynamics,…
PD1 & PDL1 Inhibitor Market – Dynamics: Regional Breakdown and Analysis
This report presents a comprehensive analysis of the PD1 & PDL1 Inhibitor Market, providing stakeholders with valuable insights into its growth trajectory, opportunities, and challenges. The study explores key market dynamics, trends, competitive landscape, and future projections to assist decision-makers in strategic planning. PD1 & PDL1 Inhibitor Market Overview Industry Insights Current market status and key drivers shaping the industry.
linkewire.com
April 14, 2025 at 7:45 AM
PD1 & PDL1 Inhibitor Market – Dynamics: Regional Breakdown and Analysis
This report presents a comprehensive analysis of the PD1 & PDL1 Inhibitor Market, providing stakeholders with valuable insights into its growth trajectory, opportunities, and challenges. The study explores key market dynamics,…
This report presents a comprehensive analysis of the PD1 & PDL1 Inhibitor Market, providing stakeholders with valuable insights into its growth trajectory, opportunities, and challenges. The study explores key market dynamics,…
🧭 Biomarkers are crucial for predicting who benefits from anti-PD-1/L1/CTLA-4 treatments.
@cp-cancercell.bsky.social
#Onco404 #Cancer #Kanser #Immunotherapy #İmmünoterapi #MedSky #OncSky #Biomarkers #PrecisionOncology #PDL1 #TMB #MSI
@cp-cancercell.bsky.social
#Onco404 #Cancer #Kanser #Immunotherapy #İmmünoterapi #MedSky #OncSky #Biomarkers #PrecisionOncology #PDL1 #TMB #MSI
May 4, 2025 at 11:34 AM
🧭 Biomarkers are crucial for predicting who benefits from anti-PD-1/L1/CTLA-4 treatments.
@cp-cancercell.bsky.social
#Onco404 #Cancer #Kanser #Immunotherapy #İmmünoterapi #MedSky #OncSky #Biomarkers #PrecisionOncology #PDL1 #TMB #MSI
@cp-cancercell.bsky.social
#Onco404 #Cancer #Kanser #Immunotherapy #İmmünoterapi #MedSky #OncSky #Biomarkers #PrecisionOncology #PDL1 #TMB #MSI
November 19, 2024 at 2:44 PM
www.ncbi.nlm.nih.gov/pmc/articles...
"Another benzimidazole compound, #albendazole, was able to target ubiquilin-4, a protein that interacts with and stabilizes #PDL1, thus promoting its proteasomal degradation."
"Another benzimidazole compound, #albendazole, was able to target ubiquilin-4, a protein that interacts with and stabilizes #PDL1, thus promoting its proteasomal degradation."
January 13, 2025 at 5:57 PM
www.ncbi.nlm.nih.gov/pmc/articles...
"Another benzimidazole compound, #albendazole, was able to target ubiquilin-4, a protein that interacts with and stabilizes #PDL1, thus promoting its proteasomal degradation."
"Another benzimidazole compound, #albendazole, was able to target ubiquilin-4, a protein that interacts with and stabilizes #PDL1, thus promoting its proteasomal degradation."
Synergistic effects of combing proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers https://www.biorxiv.org/content/10.1101/2023.09.13.557140v1
Synergistic effects of combing proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers https://www.biorxiv.org/content/10.1101/2023.09.13.557140v1
Background and purpose: Combining radiation therapy with immunotherapy may be beneficial in treatmen
www.biorxiv.org
September 15, 2023 at 11:50 PM
Synergistic effects of combing proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers https://www.biorxiv.org/content/10.1101/2023.09.13.557140v1
Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade https://www.biorxiv.org/content/10.1101/2023.12.20.572555v1
Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade https://www.biorxiv.org/content/10.1101/2023.12.20.572555v1
Metastatic cutaneous melanoma is a fatal skin cancer. Resistance to targeted and immune therapies li
www.biorxiv.org
December 21, 2023 at 11:57 PM
Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade https://www.biorxiv.org/content/10.1101/2023.12.20.572555v1
🧬💊2024 FDA approvals highlight cancer as a priority: 15 (30%) novel drugs, including the 11th PD1/PDL1 blocker.
🎯 Our mission is clear: ensure the right treatment is available and accessible to every patient. Equity in care is non-negotiable.
@oncoalert.bsky.social @oncbrothers.bsky.social
🎯 Our mission is clear: ensure the right treatment is available and accessible to every patient. Equity in care is non-negotiable.
@oncoalert.bsky.social @oncbrothers.bsky.social
January 4, 2025 at 3:54 PM
🧬💊2024 FDA approvals highlight cancer as a priority: 15 (30%) novel drugs, including the 11th PD1/PDL1 blocker.
🎯 Our mission is clear: ensure the right treatment is available and accessible to every patient. Equity in care is non-negotiable.
@oncoalert.bsky.social @oncbrothers.bsky.social
🎯 Our mission is clear: ensure the right treatment is available and accessible to every patient. Equity in care is non-negotiable.
@oncoalert.bsky.social @oncbrothers.bsky.social
On this day in Leafs history in 1991, fans predicted that Craig Berube was going to fight the North Stars' Basil McRae, as they'd fought multiple times the past two years.
Winner = Berube
www.youtube.com/watch?v=pdL1...
Winner = Berube
www.youtube.com/watch?v=pdL1...
Craig Berube vs Basil McRae Round 4
YouTube video by pjstock20
www.youtube.com
November 30, 2024 at 2:48 PM
On this day in Leafs history in 1991, fans predicted that Craig Berube was going to fight the North Stars' Basil McRae, as they'd fought multiple times the past two years.
Winner = Berube
www.youtube.com/watch?v=pdL1...
Winner = Berube
www.youtube.com/watch?v=pdL1...
Earlier this week, #BioNTech announced it is acquiring its Chinese partner Biotheus for $800M upfront + up to $150M in milestones. This deal will give BioNTech global rights to BNT327 (formerly PM8002), a PDL1 x VEGF bsAb entering Phase 2 in (N)SCLC and TNBC
investors.biontech.de/news-release...
investors.biontech.de/news-release...
BioNTech to Acquire Biotheus to Boost Oncology Strategy | BioNTech
Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to re...
investors.biontech.de
November 17, 2024 at 3:16 PM
Earlier this week, #BioNTech announced it is acquiring its Chinese partner Biotheus for $800M upfront + up to $150M in milestones. This deal will give BioNTech global rights to BNT327 (formerly PM8002), a PDL1 x VEGF bsAb entering Phase 2 in (N)SCLC and TNBC
investors.biontech.de/news-release...
investors.biontech.de/news-release...
So while we're reminded that LLMs (eg ChatGPT) are not flawless info sources so much as they're machines that make speech, here's a fun video on how people during the Edwardian Era (1901-1910) found exciting new ways to kill themselves with new tech - electricity.
www.youtube.com/watch?v=pdl1...
www.youtube.com/watch?v=pdl1...
Why Electricity Was Surprisingly Lethal In Edwardian Times
YouTube video by Progress - Science Documentaries
www.youtube.com
August 7, 2025 at 2:22 AM
So while we're reminded that LLMs (eg ChatGPT) are not flawless info sources so much as they're machines that make speech, here's a fun video on how people during the Edwardian Era (1901-1910) found exciting new ways to kill themselves with new tech - electricity.
www.youtube.com/watch?v=pdl1...
www.youtube.com/watch?v=pdl1...
Does it have any receptors? Like PDL1, EGFR, etc?
February 14, 2025 at 7:20 PM
Does it have any receptors? Like PDL1, EGFR, etc?
Is it all MHC1/PDL1? Or just EMT? Well, we didn’t see differences in MHC1 or PDL1, and activation of Zeb1 could enhance tumor growth but didn’t exclude CD8+ T cells. This indicates unique features of immune suppression to Gli2 in tumors, in parallel to EMT.
February 24, 2025 at 7:01 PM
Is it all MHC1/PDL1? Or just EMT? Well, we didn’t see differences in MHC1 or PDL1, and activation of Zeb1 could enhance tumor growth but didn’t exclude CD8+ T cells. This indicates unique features of immune suppression to Gli2 in tumors, in parallel to EMT.
pubmed.ncbi.nlm.nih.gov/31128215/
"Most surprisingly, flubendazole inhibited #PD1 levels within the tumors, but not #PDL1."
"Most surprisingly, flubendazole inhibited #PD1 levels within the tumors, but not #PDL1."
The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation - PubMed
The incidence of melanoma is increasing faster than any other cancer. In recent years, treatment of melanoma and a range of other deadly cancers has involved immunotherapy with programmed cell death p...
pubmed.ncbi.nlm.nih.gov
January 13, 2025 at 5:30 PM
pubmed.ncbi.nlm.nih.gov/31128215/
"Most surprisingly, flubendazole inhibited #PD1 levels within the tumors, but not #PDL1."
"Most surprisingly, flubendazole inhibited #PD1 levels within the tumors, but not #PDL1."
What a great pick for this year’s #lorneiandi Hertzog oration, David Underhill @cedarssinai.bsky.social presenting exciting research (recently published @nature.com !) identifying a role for PDL1 in binding fungi during phagocytosis. Shame @paulh1pjh.bsky.social couldn’t make it this year!
February 19, 2025 at 4:25 AM
What a great pick for this year’s #lorneiandi Hertzog oration, David Underhill @cedarssinai.bsky.social presenting exciting research (recently published @nature.com !) identifying a role for PDL1 in binding fungi during phagocytosis. Shame @paulh1pjh.bsky.social couldn’t make it this year!
Yes, the mechanisms and the data is in all the links that I sent. It is about the PDL1 aspect of antibodies, about P53, about IgG4, about damaging the immune-system, about frame-shifting...They are ALL mechanisms caused by the vaxx that has a well-known negative effect on cancer.
December 22, 2024 at 10:14 PM
Yes, the mechanisms and the data is in all the links that I sent. It is about the PDL1 aspect of antibodies, about P53, about IgG4, about damaging the immune-system, about frame-shifting...They are ALL mechanisms caused by the vaxx that has a well-known negative effect on cancer.
Pd1 Pdl1 Inhibitors Market Size, Growth Report 2035 www.marketresearchfuture.com/reports/pd-l...
Pd1 Pdl1 Inhibitors Market Size, Growth Report 2035
PD-L1 Inhibitors Market Industry is expected to grow from 13.11(USD Billion) in 2024 to 30 (USD Billion) by 2035. The PD-L1 Inhibitors Market CAGR (growth rate) is expected to be around 7.82% during t...
www.marketresearchfuture.com
June 13, 2025 at 6:13 PM
Pd1 Pdl1 Inhibitors Market Size, Growth Report 2035 www.marketresearchfuture.com/reports/pd-l...
Synergistic effects of combing proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers https://www.biorxiv.org/content/10.1101/2023.09.13.557140v1
Synergistic effects of combing proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers https://www.biorxiv.org/content/10.1101/2023.09.13.557140v1
Background and purpose: Combining radiation therapy with immunotherapy may be beneficial in treatmen
www.biorxiv.org
September 15, 2023 at 11:50 PM
Synergistic effects of combing proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers https://www.biorxiv.org/content/10.1101/2023.09.13.557140v1
1) KRYSTAL-7 update on pembro+adagrasib in 1st line pdl1 >50% nsclc. Tox to navigate but mPFS >27m! Further reinforcing the view that ras orchestrates TME, not just cancer cell intrinsic pathways. Massive congrats to investigators, mirati, bms #ELCC25
March 27, 2025 at 4:03 PM
1) KRYSTAL-7 update on pembro+adagrasib in 1st line pdl1 >50% nsclc. Tox to navigate but mPFS >27m! Further reinforcing the view that ras orchestrates TME, not just cancer cell intrinsic pathways. Massive congrats to investigators, mirati, bms #ELCC25